IMARC Group, a leading market research company, has recently releases report titled “Gabapentin Market Report by Dosage Form (Tablet, Capsule, Oral Solutions), Type (Generic, Branded), Application (Epilepsy, Neuropathic Pain, Restless Legs Syndrome, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Region 2023-2028.” The study provides a detailed analysis of the industry, including the global gabapentin market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Report Highlights

How big is the gabapentin market?

The global gabapentin market size reached US$ 2.1 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.9 Billion by 2028, exhibiting a growth rate (CAGR) of 5.7% during 2023-2028.

What is gabapentin?

Gabapentin, a pharmaceutical compound, is a valuable medication known for its diverse applications in the medical field. This prescription drug belongs to the class of anticonvulsants and is widely utilized in the treatment of various medical conditions. It primarily functions by altering the activity of certain chemicals in the brain, which are involved in the transmission of pain signals and seizures. This makes it an effective option for managing epilepsy and neuropathic pain, among other conditions.

Request for a sample copy of this report: https://www.imarcgroup.com/gabapentin-market/requestsample

What are the growth prospects and trends in the gabapentin industry?

The global gabapentin market has experienced notable growth in recent years, driven by the increasing prevalence of neurological disorders and chronic pain conditions worldwide. Conditions such as epilepsy, postherpetic neuralgia, diabetic neuropathy, and fibromyalgia have become more prevalent, necessitating the use of gabapentin to alleviate symptoms and improve patients' quality of life. Another important driver of the global market is the expanding aging population. As the world's population continues to age, there is a growing incidence of age-related neurological conditions and chronic pain. This demographic shift has led to a higher prescription rate of gabapentin by healthcare providers, as it is a trusted and effective treatment option for these patient groups.

Moreover, the pharmaceutical industry's ongoing efforts to develop innovative formulations and delivery methods for Gabapentin have contributed to market growth. Extended-release formulations and combination therapies that incorporate Gabapentin have been introduced to improve patient compliance and enhance the drug's efficacy. These advancements have attracted the attention of both healthcare professionals and patients, further bolstering the market. Additionally, the increasing awareness of gabapentin's therapeutic benefits among healthcare practitioners has played a pivotal role in driving its market growth. Medical professionals are recognizing the drug's potential to address a wide range of conditions beyond its initial indications. This expanded usage includes its off-label use in treating anxiety disorders, bipolar disorder, and alcohol withdrawal symptoms. The positive outcomes observed in these off-label applications have led to increased gabapentin prescriptions, thereby boosting market demand. Furthermore, the market is experiencing a shift toward online sales and e-pharmacies. Patients are increasingly turning to online platforms to purchase their medications, including gabapentin, due to convenience and cost-effectiveness. This shift has prompted pharmaceutical companies and retailers to enhance their online presence and streamline their e-commerce operations to cater to this evolving consumer behavior.

What is included in market segmentation?

The report has segmented the market into the following categories:

Breakup by Dosage Form:

  • Tablet
  • Capsule
  • Oral Solutions

Breakup by Type:

  • Generic
  • Branded

Breakup by Application:

  • Epilepsy
  • Neuropathic Pain
  • Restless Legs Syndrome
  • Others

Breakup by Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  •  

Breakup by Region:

  • North America (U.S. Canada)
  • Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Others)
  • Asia Pacific (China, India, Japan, South Korea, Indonesia, Australia, and Others)
  • Latin America (Brazil, Mexico)
  • Middle East Africa

Who are the key players operating in the industry?

The report covers the major market players including:

  • Alkem Laboratories Limited
  • Amneal Pharmaceuticals LLC
  • Apotex Inc.
  • Aurobindo Pharma Limited
  • Azurity Pharmaceuticals, Inc.
  • Cipla Inc.
  • Glenmark Pharmaceuticals Limited
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Pharmaceuticals (USA) Inc. (Zydus LifeScience)

Note: If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high-technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

USA: +1-631-791-1145 | Asia: +91-120-433-0800

Email: [email protected]

Follow us on Twitter: @imarcglobal